Available online at ScienceDirect
|
|
- Gwendoline Richardson
- 5 years ago
- Views:
Transcription
1 Journal of Crohn's and Colitis (2014) 8, Available online at ScienceDirect Comparison of long-term outcomes of S and J pouches and continent ileostomies in ulcerative colitis patients with restorative proctocolectomy-experience in subspecialty pouch center Saurabh Mukewar a, Xianrui Wu b, Rocio Lopez c, Bo Shen a, a Departments of Gastroenterology/Hepatology, The Cleveland Clinic Foundation, Cleveland, OH, USA b Department of Colorectal Surgery, The Cleveland Clinic Foundation, Cleveland, OH, USA c Department of Quantitative Health Sciences, The Cleveland Clinic Foundation, Cleveland, OH, USA Received 15 October 2013; received in revised form 20 February 2014; accepted 20 February 2014 KEYWORDS Inflammatory bowel disease; Ileal pouch anal anastomosis; Restorative proctocolectomy; S-pouch; Ulcerative colitis Abstract Background: There are no published studies comparing pouch configurations and long-term adverse outcomes. Aim: To evaluate outcomes of ulcerative colitis (UC) patients undergoing restorative proctocolectomy with S-, J- pouches or continent ileostomy (CI). Methods: We conducted a historical cohort study from the prospectively maintained Pouch Registry. Demographic and clinical variables were evaluated with univariate and multivariable analyses. Results: Fourty-five patients with S pouches and 36 with CI (33 K pouches and 3 Barnett continent ileal reservoirs) were compared with 215 J pouches serving as controls (ratio 1:2.5). In multivariable analysis, patients with S pouches were 93% less likely to develop chronic antibiotic-refractory pouchitis (CARP) than subjects with J pouches (odds ratio [OR] = 0.07; 95% confidence interval: b0.001, 0.54; pb0.001). However, no significant difference in the frequency of CARP was found between the CI and J pouch groups (OR = 0.68; 95% confidence interval: 0.17, 2.00, p = 0.40). Patients with S pouches were 8 times more likely (95% confidence interval: 3.7, 17.5; p b 0.001) and patients with CI 5.6 had times more likely (95% confidence Abbreviations: AID, autoimmune disorders; BCIR, Barnett continent intestinal reservoir; CARP, chronic antibiotic-refractory pouchitis; CD, Crohn's disease; CI, continent ileostomy; EIM, extra-intestinal manifestations; IQR, interquartile range; IC, indeterminate colitis; IPAA, ileal pouch anal anastomosis; IPS, irritable pouch syndrome; mpdai, the modified Pouch Disease Activity Index; NSAID, non-steroidal anti-inflammatory drugs; OR, odds ratio; PSC, primary sclerosing cholangitis; SD, standard deviation; TNF, tumor-necrosis factor; UC, ulcerative colitis. Grant support: This study was partially supported by a research grant from the Crohn's and Colitis Foundation of America (to B.S.). Corresponding author at: Department of Gastroenterology/Hepatology-A31, The Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195, USA. Tel.: ; fax: address: shenb@ccf.org (B. Shen) / 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V.
2 1228 S. Mukewar et al. interval: 2.4, 13.3; p b 0.001) to have pouch surgery-related complications than those with J pouches. There was no difference in the rate of CD of the pouch, pouch-associated hospitalization and pouch failure between the S- pouch, CI and J- pouch groups. Conclusions: Patients with J pouches appeared to have a greater risk for chronic pouchitis than those with S-pouches and but had a lower risk for developing pouch surgery-related complications than those with S pouches or CI European Crohn's and Colitis Organisation. Published by Elsevier B.V. 1. Introduction Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) has become the surgical procedure of choice for patients with ulcerative colitis (UC) who require surgery. Various designs for the pouch configuration have been developed over the past four decades. In 1969, Kock et al. 1 created the continent ileostomy (CI), named Kock pouch or K pouch. In 1978, Parks et al. 2 for the first time, constructed a 3-limb S pouch. This was followed by a 2-limb J pouch design by Utsunomiya et al. 3 in 1980 and a 4-limb W pouch design by Nicholls et al. in Currently, the majority of UC patients who require restorative proctocolectomy elect to have a J pouch, whenever technically feasible. A staged J-pouch surgery with stapled anastomosis without mucosectomy has become a standard procedure. On the other hand, the S pouch is mainly performed in those with technical difficulties for stapled anastomoses, such as patients with mucosectomy (for colitis-associated rectal neoplasia) or a short mesentery. The K pouch is often constructed for patients who have contraindications for J or S pouches, such as those with poor anal sphincter function, as a primary indication, or for selected patients who have failed J or S pouches, as a rescue or secondary operation. Each pouch configuration offers certain advantages over the others. For example, pouch inlet and outlet angulation (namely afferent limb and efferent limb syndromes, respectively) are more common with S pouches than J pouches. 5,6 However, there are no published studies addressing the longterm outcome of different pouch designs, in particular, a comparison of the occurrence of chronic antibiotic-refractory pouchitis (CARP), Crohn's disease (CD) of the pouch, pouch surgery-related complications, and pouch failure based on the pouch configuration. At our Pouch Center, we noticed that patients with an S pouch often had mechanical issues, such as afferent and efferent limb syndromes. On the other hand, we also found that pouch inflammation was not common in patients with S pouches or with CI. Therefore, we hypothesized that the long-term outcomes of ileal pouches vary with the configuration of pouch. The aim of the study was to evaluate long-term outcomes of UC patients undergoing restorative proctocolectomy with an S pouch, J pouch or CI. 2. Patients and methods 2.1. Patients The patients for this historical cohort study were identified from our Institutional Review Board (IRB)-approved Pouchitis Registry from 2002 to Study and control groups The study group consisted of patients with S or CI. CI consisted of patients with K pouches or Barnett continent intestinal reservoir (BCIR). Patients with J pouches, who were randomly selected from the 1550-case Pouch Registry, served as the control group, with a study to control ratio of approximately 1: Inclusion and exclusion criteria Patients with UC, indeterminate colitis (IC), or Crohn's colitis who underwent restorative proctocolectomy and intestinal pouches with S, K (or BCIR) or J configurations were included. BCIR was considered as a form of CI and was also included. Patients with familial adenomatous polyposis and other pouch configurations were excluded Demographic and clinical variables Demographics, history of smoking, and clinical characteristics of IBD, including duration of IBD, disease extent, history of the use of anti-tumor-necrosis factor (TNF) biologics (before and/ or after colectomy), the postoperative long-term use of nonsteroid anti-inflammatory drugs (NSAID), family history of IBD, extra-intestinal manifestations (EIM), concurrent autoimmune disorders (AID), and indication for colectomy, were retrieved. The clinical variables were defined as follows: smoking, smoking more than seven cigarettes a week since the surgery; preoperative diagnosis, including UC, IC, and Crohn's colitis; extent of colitis, defined on the basis of anatomical distribution of IBD at the time of colectomy and determined by a combined assessment of endoscopic, radiographic, macroscopic, and histopathological data; duration of IBD, defined at the time from the diagnosis of IBD to the completion of IPAA with ileostomy closure; family history of IBD, CD or UC in the first-degree relatives; preoperative biological therapy, any use of biological agent for IBD before colectomy; indication for proctocolectomy and IPAA, the primary reason for surgery based on clinical presentation and preoperative diagnostic studies; EIM, including musculoskeletal manifestations peripheral arthritis, ankylosing spondylitis and sacroilitis, hepatobiliary diseases primary sclerosing cholangitis, skin manifestations pyoderma gangrenosum, erythema nodosum and aphthous stomatitis, ocular manifestations uveitis, scleritis and episcleritis, vascular disorders thromboembolic events; autoimmune diseases defined by the presence of AID including adult-onset asthma autoimmune thyroid disease, type I diabetes, rheumatoid arthritis, autoimmune hemolytic anemia, celiac disease, Sjögren or
3 Pouch type and long-term outcomes 1229 Raynaud's disease with a history or coexisting presence of autoantibodies. The diagnosis of AID was confirmed by clinical evaluation and documentation of ICD-9-CM codes and current and/or history of disease directed medical therapy. Both electronic and paper charts from referring clinicians were reviewed by one of the senior investigators (B.S.) to diagnose AID. We also evaluated significant comorbidities including congestive heart failure, coronary artery bypass graft, chronic obstructive pulmonary disease, renal insufficiency, liver failure, non-pouch-related cancer and stroke. Data pertaining to the pouch surgery (staging of pouch surgery and indications for colectomy), duration of pouch, post-operative use of biologics and/or immunomodulators, and number of visits to the Pouch Center were compared between study and the control groups. Pouch related variables were defined as follows: duration of the pouch, the interval between the ileostomy closure and the time of pouch failure or the most recent follow-up at the Pouch Center; post-operative use of immunomodulators, the use of immunomodulators for pouch-related disorders or AID after pouch construction; post-operative use of biological agents, the use of anti-tnf biologics for pouch-related disorders or AID after pouch construction Diagnostic criteria for pouch disorders Patients were considered to have a normal pouch if they were asymptomatic, with no endoscopic and no or minimum histologic inflammation and fewer than three episodes of antibiotic-responsive pouchitis (symptoms responding to a 2-week, single-agent antibiotic) per year with the last episode occurring at least 6 months prior. 7 Pouchitis was defined as a condition with the modified Pouchitis Disease Activity Index (mpdai) scores N 5. 8 Acute pouchitis was defined as pouchitis that responded to a short course of a single antibiotic, which included antibioticresponsive (b 4 episodes per year) and antibiotic-dependent pouchitis (N 4 episodes per year, and requires long-term, continuous antibiotic or probiotic therapy to maintain remission). CARP was defined as a condition where a patient failed to respond to a 4-week course of a single antibiotic (metronidazole or ciprofloxacin), requiring prolonged therapy of N4 weeks consisting of N 2 antibiotics, oral or topical 5-aminosalicylate, corticosteroid therapy, immunomodulator therapy or therapy with anti-tnf biologics. CD of the pouch was diagnosed if there were nonsurgery-related perianal fistulae, granulomas on histology or inflammation and ulcerations in the afferent limb or in the small bowel on endoscopy in the absence of NSAID use. All patients with CD of the pouch underwent clinical, endoscopic, radiographic, and histologic evaluation. 5,9 Irritable pouch syndrome (IPS) was defined as the presence of abdominal pain, pelvic discomfort and diarrhea with no inflammation of the afferent limb, pouch or cuff on endoscopy. These symptoms had persisted for at least 12 weeks in 12 months prior to the data entry. Pouch-related mechanical and structural complications included inlet or outlet obstruction, pouch prolapse, nipple valve dysfunction or strictures (from the K pouch or BCIR), trapped ovarian syndrome, pouch bezoar or foreign body, pouch leak and anastomotic sinus. Hospitalization was defined as admission and hospital stay for more than 24 h due to a pouch order as a primary diagnosis, which did not include admission for elective pouch excision or diversion surgery. Pouch failure was defined as the need for permanent diversion or revision of the ileal pouch, with or without pouch excision Clinical practice pattern The Cleveland Clinic Pouch Center has been a national and international referral center for various ileal pouch disorders. At the Cleveland Clinic, the J pouch has been the preferred configuration for majority of the patients over the study period. The S pouch was generally created in patients with difficulty with reach or patients with rectal dysplasia undergoing mucosectomy. The K pouch was constructed under following circumstances: 1) the primary K pouch: The pouch was constructed for patients with poor anal sphincter function, in whom the construction of J or S pouches was contraindicated. 2) The secondary K pouch converted from failed J or S pouches: A K pouch was constructed using the old J or S pouches 10 ; or 3) secondary neo-k pouch: In patients with J- or S-pouch failure, the old pouch was excised and a new K pouch was constructed. BCIR, not a standard practice at our institution, was constructed at outside institutions, typically as primary pouches. All patients had routine follow-up at the Pouch Center staffed by an IBD specialist (B.S.). Typically, we followed patients with CARP, CD of the pouch and refractory cuffitis every 3 6 months, acute pouchitis or cuffitis every 6 12 months, and yearly for those with normal pouches Outcome measurement Primary outcome was the development of CARP, CD of the pouch, pouch-related mechanical/structural complications, pouch-associated hospitalization and pouch failure at the time of the most recent visit to the Pouch Center Statistical analysis Data are presented as mean ± standard deviation (SD), median (interquartile range [IQR]) or N (%). A univariable analysis was performed to assess differences between J, S and K pouches. Analysis of variance (ANOVA) or the nonparametric Kruskal Wallis tests were used to compare continuous factors and Pearson's chi-square tests were used for categorical variables. Ad-hoc pair-wise comparisons were done using a significance criterion of (0.05/3) in order to account for multiple comparisons. In addition, a multivariable logistic regression analysis was used to assess the impact of pouch type on post-operative development of CARP, pouch-related mechanical/structural complications and CD of the pouch. The final models were chosen using an automated stepwise variable selection method performed on 1000 bootstrap samples. Pouch type and smoking were included in the models and all other factors were considered for inclusion; variables with inclusion rates of at least 30% were kept in the models. None of the patients with S pouches developed CARP; hence a penalized maximum
4 1230 S. Mukewar et al. likelihood and the likelihood ratio tests were used for the regression model. In addition, a time-to-pouch failure analysis was performed. Follow-up time was defined as duration of pouch from creation to either failure or last follow-up visit. Kaplan Meier plots were constructed and log-rank tests were used to compare the groups; multivariable Cox Regression analysis was used to adjust for smoking. P b 0.05 was considered statistically significant. All analyses were performed using SAS (version 9.2, The SAS Institute, Cary, NC) and R (version , The R Foundation for Statistical Computing, Vienna, Austria). 3. Results 3.1. Demographics and IBD-related features Forty-five patients had S pouches and 36 had CI (including 21 primary K pouches, 3 BCIR, 4 secondary K pouches, and 8 secondary neo-k pouches). The control group consisted of 215 patients with J pouches. The demographic and clinical features of the S, CI and J pouch groups were compared (Tables 1 and 2). Patients with J pouches were more likely to Table 1 Demographic and clinical characteristics. Factor S Continent ileostomy J p-value (N = 45) (N = 36) (N = 215) Mean age at diagnosis of ulcerative colitis, years a 22.2 ± ± ± Male gender 16(35.6) b 17(47.2) 122(56.7) c Race 0.42 Caucasian 45(100.0) 36(100.0) 205(95.3) African American 0 0 4(1.9) Others 0 0 6(2.8) Smoking 0.99 Never 39(86.7) 30(83.3) 180(83.7) Ex-smoker 4(8.9) 4(11.1) 24(11.2) Current smoker 2(4.4) 2(5.6) 11(5.1) Chronic use of NSAIDs 4(8.9) 2(5.6) 21(9.8) 0.72 Family history of IBD a 0.31 None 32(72.7) 29(80.6) 178(82.8) Crohn's disease 2(4.5) 3(8.3) 13(6.0) Ulcerative colitis 10(22.7) 4(11.1) 24(11.2) Pre-operative diagnosis Crohn's colitis 1(2.2) 4(11.1) 3(1.4) Indeterminate colitis 3(6.7) 4(11.1) 14(6.5) Ulcerative colitis 41(91.1) 28(77.8) b 198(92.1) d Extra-intestinal manifestations a 18(40.0) 13(37.1) 81(37.7) 0.95 Primary sclerosing cholangitis 2(4.4) 0 8(3.7) 0.47 Autoimmune diseases 8(17.8) 1(2.8) 22(10.2) Co-morbidities 3(6.7) 2(5.6) 16(7.4) 0.91 Extent of colitis a 0.21 Pancolitis 43(97.7) 35(100.0) 202(94.0) Left-sided colitis or proctitis 1(2.3) 0 13(6.0) Fulminant colitis a 4(9.1) 2(5.7) 22(10.2) 0.7 Pre-operative biological use a 8(18.2) 4(11.1) 32(15.0) 0.68 Duration of IBD from diagnosis to pouch surgery (years) a 5.0[3.0,10.5] d 8.0[5.0,15.0] c 6.0[3.0,12.0] Indication for colectomy a Refractory to medical management 37(84.1) d 36(100.0) b,c 184(85.6) d Dysplasia 7(15.9) 0 31(14.4) A significance level of was used for pairwise ad-hoc comparisons. a Data not available for all subjects. Missing values: age at diagnosis of UC = 4, family history of IBD = 1, indication for colectomy = 1, extent of UC = 2, fulminant colitis = 2, pre-operative biological therapy = 2, duration of IBD from diagnosis to pouch surgery (years) = 2. Values presented as Mean ± SD with ANOVA; Median [P25, P75] with Kruskal Wallis test, or N (%) with Pearson's chi-square test unless otherwise stated. b Significantly different from J. c Significantly different from S. d Significantly different from continent ileostomy.
5 Pouch type and long-term outcomes 1231 Table 2 Long-term pouch outcomes. Factor S Continent ileostomy J p-value be male than those with S pouches (56.7% vs. 35.6%; p = 0.028). A greater number of patients with J pouches had a pre-operative diagnosis of classic UC than CI patients (92.1% vs. 77.8%; p = 0.014). Patients with CI (median = 8.0 years; IQR: 5.0, 15.0) had a significantly longer duration of IBD than those with S pouches (median = 5.0 years; IQR: 3.0, 10.5; p = 0.035). None of the patients who had CI had colectomy (N = 45) (N = 36) (N = 215) Mean age at pouch surgery a 30.2 ± ± ± Number of stages for pouch surgery a b b 1(2.9) c,d 8(3.7) b 2 32(72.7) 16(45.7) 154(71.6) 3 5(11.4) 2(5.7) 43(20.0) 4 or redo 7(15.9) 16(45.7) 10(4.7) Median duration from pouch to last visit (years) 15.0[11.0,21.0] b,c 20.5[13.5,28.5] c,d 9.0[5.0,14.0] b,d b0.001 Median duration from first Pouch Center visit to date a 5.0[1.00,7.0] 4.0[1.5,5.0] 5.0[2.0,6.0] 0.33 Post-operative use of immunomodulators 3(6.7) 4(11.1) 16(7.4) 0.72 Post-operative use of biologics 1(2.2) 2(5.6) 22(10.2) 0.17 Final pouch diagnosis Acute pouchitis 7(15.6) c 5(13.9) c 78(36.3) b,d Chronic antibiotic-refractory pouchitis 0 c 3(8.3) 28(13.0) d Crohn's disease of the pouch 11(24.4) 9(25.0) 40(18.6) 0.51 Pouch-related mechanical and structural complications 20(44.4) c 12(33.3) c 20(9.3) b,d b0.001 Number of visits to pouch center 1.00[1.00,2.0] 1.00[1.00,3.0] 1.00[1.00,3.0] 0.75 Post-op hospitalizations 4(8.9) 5(13.9) 25(11.6) 0.78 Pouch failure 3(6.7) 3(8.3) 17(7.9) 0.95 Cause of pouch failure 0.86 No failure 42(93.3) 33(91.7) 198(92.1) Pouch-surgery related complications 2(4.4) 2(5.6) 4(1.9) Chronic antibiotic-refractory pouchitis 0 0 1(0.47) Crohn's disease of the pouch 1(2.2) 1(2.8) 10(4.7) Cancer 0 0 2(0.93) Median follow up (years) a 15.0[10.0,21.0] b,c 21.0[14.0,29.0] c,d 9.0[4.0,14.0] b,d b0.001 a Data not available for all subjects. Missing values: age at pouch creation = 1, stage of pouch surgery = 2, first pouch center visit to date = 31, follow-up of pouch failure (years) = 1. Values presented as Mean ± SD with ANOVA; Median [P25, P75] with Kruskal Wallis test, or N (%) with Pearson's chi-square test unless otherwise stated. b Significantly different from continent ileostomy. c Significantly different from J. d Significantly different from S. for dysplasia, as compared to 14.4% and 15.9% of those with J or S pouches, respectively (p = 0.047). There were no differences in the age at the diagnosis of IBD, ethnic background, family history of IBD, history of smoking, NSAID use, EIM, PSC, extent of colitis, history of fulminant colitis, pre-operative anti-tnf biologic therapy, age at pouch surgery and current age of patients between the study and control groups Pouch configuration and outcomes Figure 1 Long-term adverse outcomes in patients with different pouch configurations. Stage of surgery was significantly different between the three groups, largely due to the nature of indication for colectomy and for the CI (p b 0.001). Final diagnosis of the pouch was also significantly different (Fig. 1). Patients with S or CI were less likely to have CARP than those with J pouches (15.6% in the S vs. 13.9% in the CI vs. 36.3% in the J groups; p = 0.002). CARP was more common in patients with J pouches than those with S pouches (13.0% vs. 0%; p = 0.013). Patients with S pouches or CI were more likely to have pouch surgery-related complications than those with J pouches (44.4% in S vs. 33.3% in CI vs. 9.3% in J; p b 0.001). There was no difference in pouch surgery-related complications between the patients with S pouches and those with CI (p = 0.31). The
6 1232 S. Mukewar et al. Table 3 Categorization of pouch-related mechanical and surgical complications. Factor S Continent ileostomy J p-value (N = 20) (N = 12) (N = 20) Inlet or distal pouch prolapse 4(20.0) 0 1(5.0) 0.12 Afferent limb syndrome 1(5.0) 0 1(5.0) 0.73 Inlet obstruction from intrinsic stricture 2(10.0) 2(16.7) 4(20.0) 0.67 Outlet obstruction from bowel angulation or long limb 7(35.0) 0 2(10.0) Outlet obstruction from anastomotic stricture 7(35.0) NA 3(15.0) Nipple valve dysfunction NA 5(41.7) NA NA Anastomotic sinus 0 NA 0 The tip of the J leak NA NA 1(5.0) NA Pouch sinus 2(10.0) a 0 a 12(60.0) b,c b0.001 Pouch bezoars or foreign bodies 0 1(8.3) Nipple valve stricture NA 1(8.3) NA NA Trapped ovarian syndrome 1(5.0) a Significantly different from J. b Significantly different from S. c Significantly different from continent ileostomy. median duration of pouch was significantly different between the three groups (15.0; IQR: 11.0, 21.0 years in the S vs. 20.5; IQR: 13.5, 28.5 years in the K vs. vs. 9.0; IQR: 5.0, 14.0 years in the J; p b 0.001). There were no differences in the use of anti-tnf biologics or immunomodulators after pouch surgery, number of visits to the Pouch Center and hospitalization and pouch failure for pouch-related disorders between the three groups Chronic antibiotic-refractory pouchitis Table 4 presents the multivariable analysis for development of CARP. After adjusting for smoking, patients with S pouches were 93% less likely to develop CARP than subjects with J pouches [S vs. J: likelihood ratio 0.07; 95% confidence interval: b0.001, 0.54; p b 0.001]. On the other hand there was no evidence to suggest a significant difference between the CI and J pouch groups (CI vs. J: odds ratio [OR) 0.68; 95% confidence interval: 0.17, 2.00, p = 0.40] Pouch-related mechanical and structural complications Table 3 presents a summary and Table 5 presents the multivariable analysis for pouch-related mechanical and structural complications. After adjusting for smoking, EIM and age at time of pouch surgery, patients with S pouches were 8 times more likely to have pouch-related mechanical and structural complications than subjects with J pouches (95% confidence interval: 3.7, 17.5; p b 0.001). Also, patients with CI were 5.6 times more likely to have pouch-related mechanical and structural complications than patients with J pouches (95% confidence interval: 2.4, 13.3; p b 0.001) Crohn's disease of the pouch Table 6 presents the multivariable analysis for the risk for the development of CD of the pouch. After adjusting for smoking, family history of CD, age at the time of pouch construction and pre-op diagnosis, there was no evidence to suggest that pouch type was associated with the occurrence of CD of the pouch Pouch failure There was no evidence of a significant difference in pouch failure between the three groups (Fig. 2). On multivariable analysis, pouch type was not associated with risk for pouch failure (Table 7) Cleveland Clinic pouches vs. non-cleveland Clinic pouches Table 4 Risk for chronic-antibiotic refractory pouchitis: multivariable logistic regression analysis. Factor Odds ratio p-value (95% confidence interval) Continent ileostomy 0.68 (0.17, 2.00) 0.40 vs. J pouch S vs. J pouch 0.07 (b0.001, 0.54) Smoking 2.4 (1.01, 5.60) There were no significant differences in type of pouches, pouch failure rate, CARP and CD of the pouch. However, the rate of pouch procedure-related complications was lower in the Cleveland Clinic pouches (Table 8). 4. Discussion This is the first study comparing the various long-term adverse outcomes of the different pouch designs in patients with IBD. The majority of studies comparing pouch designs 4,11 17 have either focused on functional outcomes or short-term
7 Pouch type and long-term outcomes 1233 Table 5 Risk for pouch surgery-related complications: multivariable logistic regression analysis. Factor Odds ratio (95% confidence interval) p-value Continent ileostomy 5.6 (2.4, 13.3) b0.001 vs. J pouch S vs. J pouch 8.0 (3.7, 17.5) b0.001 Extra-intestinal 0.38 (0.18, 0.81) manifestations Age at time of 0.86 (0.75, 1.00) pouch construction (5 year increase) Smoking 1.4 (0.53, 3.50) 0.51 complications. Our study showed that in the long run, patients with S pouch were 8 times or CI were 5.6 times more likely to have pouch-related mechanical/structural complications than those with J pouches. On the other hand, patients with S pouches were 93% less likely to develop pouchitis than patients with J pouches. The trade-off of mechanical/structural complications and pouchitis provides a new insight for patients, colorectal surgeons, and IBD specialists to select the appropriate pouch configuration after colectomy for UC. Pouch-related mechanical and structural complications such as anastomotic leaks, fistulae, sinuses, prolapse, strictures, afferent limb syndrome and efferent limb syndrome are seen in patients undergoing pouch construction. While few of these complications can be managed conservatively, most of these require surgical or endoscopic intervention. A recent meta-analysis 18 comparing J, S and W pouch showed no difference in pouch-related mechanical/structural complications (anastomotic leak, anastomotic stricture, pelvic sepsis and small bowel obstruction). However, the included studies had fewer patients (less than 300 in total), shorter follow-up and the lack of well-defined criteria for long-term pouchrelated disorders. For example, patients with pouch stricture secondary to CD of the pouch could have been mislabeled as a pouch-related mechanical/structural complication. In addition, the studies primarily discussed immediate post-operative Table 6 Crohn's disease of the pouch: multivariable logistic regression analysis. Factor Odds ratio (95% confidence interval) p-value Continent ileostomy 1.3 (0.54, 3.20) 0.56 vs. J pouch S vs. J pouch 1.4 (0.62, 3.00) 0.45 Family history of 5.0 (1.8, 13.8) Crohn's disease Age at time of 0.87 (0.76, 0.98) pouch construction (5 year increase) Smoking 0.88 (0.36, 2.20) 0.78 Pre-op diagnosis of ulcerative colitis 0.51 (0.21, 1.20) 0.14 surgical complications. Results from our current study showed a greater long-term risk of pouch-related mechanical/structural complications in patients with S pouches or CI than those with J pouches. We suspect that patients with S pouches or CI are prone to these complications owing to the anatomy of the pouch and the way in which the pouch is constructed. The construction of S or CI can be technically demanding. Complications such as afferent and efferent limb syndromes were more commonly seen in the patients with S pouches as a consequence of triplicated design and potential placement of a long efferent limb. On the other hand, the main pouch-related mechanical/structural complication in the CI was malfunction of the nipple valve. In contrast, J pouches were more prone to the development of anastomotic sinuses, probably due to the risk of anastomotic tension during its construction. Colorectal surgeons may find it difficult for the pouch body to reach the rectal stump due to the length of mesentery or a body habitus. This can cause anastomotic tension or compromise of perfusion of the distal pouch leading to anastomotic leak (acute) or sinus (chronic) and ischemic pouchitis. 19 In fact, ischemic pouchitis is likely a cause of CARP in some patients. 19 In contrast, the construction of S pouch maygiveanadditional2 3 cm length of the efferent limb to reach the anal transitional zone. Similarly, the reach is not a main issue during construction of CI. Twenty-three to 46% patients develop pouchitis years after pouch surgery. 20,21 Various risk factors have been associated with pouchitis genetic polymorphisms of interleukin-1- receptor antagonist and NOD2/CARD 25,26 non-carrier status of TNF allele, 22,27 extensive UC, 21,28,29 backwash Table 7 Factor Figure 2 Kaplan Meier curve: pouch survival. Pouch failure: multivariable Cox Regression analysis. Hazard ratio (95% confidence interval) p-value J vs. S pouch 1.4 (0.40, 5.0) 0.59 Smoking 1.4 (0.46, 4.3) 0.55
8 1234 S. Mukewar et al. ileitis, 29 pre-proctocolectomy thrombocytosis, 30,31 preoperative corticosteroid use, 31 the presence of EIM, especially PSC, 20,28,31 34 the presence of perinuclear antineutrophil cytoplasmic antibodies, being a non-smoker 7,31,38 and the regular use of NSAIDs. 7,28 However, none of these studies assessed pouch configuration as a risk factor for CARP. Meta-analysis by Lovegrove et al. 18 showed no difference between patients with J or S pouches for the risk for CARP. However, pouchitis was not stratified into acute pouchitis and CARP in this study. Clinically, acute pouchitis and CARP behave as different clinical entities, with latter being more like IBD. Our observations are contrary to these results. We evaluated various conventional risk factors, which have been known to be associated with chronic pouchitis amongst the two groups extensive UC, backwash ileitis, pre-operative corticosteroid use, the presence of EIM, PSC, history of smoking and NSAID use and could not identify any difference. There were no significant differences in the use of steroids, biologics or fulminant colitis amongst the groups. Therefore, we paid attention to non-conventional factors and one of them was pouch configuration, based on our clinical observation of a large number of patients in our Pouch Center. We found that J pouch configuration was independently associated with pouchitis. The obvious difference in the frequency of pouchitis between J vs. other S pouches or CI suggested that mechanical reasons could play a role in the pathogenesis of CARP. One of them could be a greater stretch of mesenteric vasculature during J pouch construction. CD of the pouch is one of the most dreaded adverse event following the ileal pouch surgery. It is estimated that 2.7% to 13% of pouch patients develop CD of the pouch. Smoking, 7 family history of CD, 9,39 ethnicity, 40,41 longer duration of pouch, 42 pre-operative diagnosis of IC 42 and seropositivity for anti-saccharomyces cerevisiae-iga antibody 39 are some of the risk factors associated with this condition. Although the majority of these studies did not include the pouch configuration as a study variable, 9,39,40,42 one study by our group assessed for the pouch configuration and failed to show it as a risk factor for CD of the pouch. 7 Studies comparing different pouch configurations, including the recent meta-analysis, did not include CD of the pouch as an outcome. This is likely because CD of the pouch is being increasingly recognized, and most of these studies were conducted in 1980s and 90s and had a shorter duration of follow-up of patients and a smaller sample size. Results from our study confirm that the pouch configuration was not a risk factor for CD of pouch. According to the results of a meta-analysis of nearly 9000 patients, pouch failure occurred in 8.5% of the patients. 43 CD of the pouch, chronic pouchitis and pelvic sepsis 44,47 are the main causes for pouch failure. A prospective study of 634 patients 48 noted a greater pouch failure rate in J and S pouches than W or K pouches. However, our observations are contrary to their study, as we did not identify any difference in pouch failure rate amongst the groups. The discrepancy may result from the sample size, duration of follow-up, and practice setting. The results of this study have several clinical implications. Our study shows that the risk for developing CARP and pouch-related mechanical/structural complications varies with pouch design, suggesting the role of surgical techniques and mechanical factors in their etiopathogenesis. The tradeoff for the construction of a S pouch or CI with a lower risk for CARP and a higher risk for pouch-related mechanical/surgical complications vs. J pouches with a higher risk for CARP and a lower risk for the mechanical/surgical complications should be carefully balanced. Our study has several limitations. Although the cohort had a range of healthy and diseased pouch conditions, there might have been a referral bias due to the nature of our practice. As pouchitis clinic is a major referral center, we see patients referred from the Department of Colorectal Surgery of the Cleveland Clinic as well as from outside hospitals and practices. A sizeable number of patients were referred to the pouchitis clinic for pouch related problems from elsewhere. Finally, CD of the pouch and pouch failure can occur many years after the construction of pouch. Despite the fact that this was a long-term study, patients with S pouches or CI had a longer follow-up than those with J pouches. Reliability in follow-up of pouch patients may have been better in the recent years, with new guidelines and recommendations. Thus, patients with J pouches might have had a better follow-up than those with S pouches or CI. In conclusion, this study shows that different pouch designs are associated the development of CARP and pouch-related mechanical/structural complications. The findings are of prognostic benefit and can help patients and clinicians choose a proper pouch design, balancing the trade-off of advantages and disadvantages. Table 8 pouches. Characteristic Comparison of pouch configurations and major adverse outcome between Cleveland Clinic and Non-Cleveland Clinic NonCleveland Clinic pouches (N = 129) Cleveland Clinic pouches (N = 167) Type of the pouch 0.49 J pouch 91 (70.5) 124 (74.3) S pouch 19 (14.7) 26 (15.6) Continent ileostomy 19 (14.7) 17 (10.2) Pouch failure 14 (10.9) 9 (5.4) Chronic antibiotic-refractory pouchitis 14 (10.9) 17 (10.2) 0.85 Crohn's disease of the pouch 24 (18.6) 36 (21.6) 0.53 Pouch procedure-related complications 32 (24.8) 20 (12.0) p-value
9 Pouch type and long-term outcomes 1235 Disclosure The authors declared no financial conflicts of interest. References 1. Kock NG. Intra-abdominal reservoir in patients with permanent ileostomy. Preliminary observations on a procedure resulting in fecal continence in five ileostomy patients. Arch Surg 1969; 99(2): Parks AG, Nicholls RJ. Proctocolectomy without ileostomy for ulcerative colitis. Br Med J 1978;2(6130): Utsunomiya J, Iwama T, Imajo M, Matsuo S, Sawai S, Yaegashi K, et al. Total colectomy, mucosal proctectomy, and ileoanal anastomosis. Dis Colon Rectum 1980;23(7): Nicholls RJ, Pezim ME. Restorative proctocolectomy with ileal reservoir for ulcerative colitis and familial adenomatous polyposis: a comparison of three reservoir designs. Br J Surg 1985; 72(6): Shen B, Remzi FH, Lavery IC, Lashner BA, Fazio VW. A proposed classification of ileal pouch disorders and associated complications after restorative proctocolectomy. Clin Gastroenterol Hepatol 2008;6(2): Wu XR, Kiran RP, Mukewar S, Remzi FH, Shen B. Diagnosis and management of pouch outlet obstruction caused by common anatomical problems after restorative proctocolectomy. J Crohns Colitis 2014;8(4): Shen B, Fazio VW, Remzi FH, Brzezinski A, Bennett AE, Lopez R, et al. Risk factors for diseases of ileal pouch-anal anastomosis after restorative proctocolectomy for ulcerative colitis. Clin Gastroenterol Hepatol 2006;4(1): Shen B, Achkar JP, Connor JT, Ormsby AH, Remzi FH, Bevins CL, et al. Modified pouchitis disease activity index: a simplified approach to the diagnosis of pouchitis. Dis Colon Rectum 2003;46(6): Shen B, Remzi FH, Hammel JP, Lashner BA, Bevins CL, Lavery IC, et al. Family history of Crohn's disease is associated with an increased risk for Crohn's disease of the pouch. Inflamm Bowel Dis 2009;15(2): Lian L, Fazio VW, Remzi FH, Shen B, Dietz D, Kiran RP. Outcomes for patients undergoing continent ileostomy after a failed ileal pouch-anal anastomosis. Dis Colon Rectum 2009;52(8): de Silva HJ, de Angelis CP, Soper N, Kettlewell MG, Mortensen NJ, Jewell DP. Clinical and functional outcome after restorative proctocolectomy. Br J Surg 1991;78(9): Neilly P, Neill ME, Hill GL. Restorative proctocolectomy with ileal pouch-anal anastomosis in 203 patients: the Auckland experience. Aust N Z J Surg 1999;69(1): Nasmyth DG, Williams NS, Johnston D. Comparison of the function of triplicated and duplicated pelvic ileal reservoirs after mucosal proctectomy and ileo-anal anastomosis for ulcerative colitis and adenomatous polyposis. Br J Surg 1986;73(5): OreslandT,FasthS,NordgrenS,HallgrenT,HultenL.Aprospective randomized comparison of two different pelvic pouch designs. Scand J Gastroenterol 1990;25(10): Romanos J, Samarasekera DN, Stebbing JF, Jewell DP, Kettlewell MG, Mortensen NJ. Outcome of 200 restorative proctocolectomy operations: the John Radcliffe Hospital experience. Br J Surg 1997;84(6): Schoetz Jr DJ, Coller JA, Veidenheimer MC. Ileoanal reservoir for ulcerative colitis and familial polyposis. Arch Surg 1986; 121(4): Svaninger G, Nordgren S, Oresland T, Hulten L. Incidence and characteristics of pouchitis in the Kock continent ileostomy and the pelvic pouch. Scand J Gastroenterol 1993;28(8): Lovegrove RE, Heriot AG, Constantinides V, Tilney HS, Darzi AW, Fazio VW, et al. Meta-analysis of short-term and longterm outcomes of J, W and S ileal reservoirs for restorative proctocolectomy. Colorectal Dis 2007;9(4): Shen B, Plesec TP, Remer E, Kiran P, Remzi FH, Lopez R, et al. Asymmetric endoscopic inflammation of the ileal pouch: a sign of ischemic pouchitis? Inflamm Bowel Dis 2010;16(5): Penna C, Dozois R, Tremaine W, Sandborn W, LaRusso N, Schleck C, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996;38(2): Fazio VW, Ziv Y, Church JM, Oakley JR, Lavery IC, Milsom JW, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg 1995;222(2): Aisenberg J, Legnani PE, Nilubol N, Cobrin GM, Ellozy SH, Hegazi RA, et al. Are panca, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients. Am J Gastroenterol 2004;99(3): Brett PM, Yasuda N, Yiannakou JY, Herbst F, Ellis HJ, Vaughan R, et al. Genetic and immunological markers in pouchitis. Eur J Gastroenterol Hepatol 1996;8(10): Carter MJ, Di Giovine FS, Cox A, Goodfellow P, Jones S, Shorthouse AJ, et al. The interleukin 1 receptor antagonist gene allele 2 as a predictor of pouchitis following colectomy and IPAA in ulcerative colitis. Gastroenterology 2001;12(4): Meier CB, Hegazi RA, Aisenberg J, Legnani PE, Nilubol N, Cobrin GM, et al. Innate immune receptor genetic polymorphisms in pouchitis: is CARD15 a susceptibility factor? Inflamm Bowel Dis 2005;11(11): Paye F, Penna C, Chiche L, Tiret E, Frileux P, Parc R. Pouchrelated fistula following restorative proctocolectomy. Br J Surg 1996;83(11): Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology 1994; 107(6): Achkar JP, Al-Haddad M, Lashner B, Remzi FH, Brzezinski A, Shen B, et al. Differentiating risk factors for acute and chronic pouchitis. Clin Gastroenterol Hepatol 2005;3(1): Schmidt CM, Lazenby AJ, Hendrickson RJ, Sitzmann JV. Preoperative terminal ileal and colonic resection histopathology predicts risk of pouchitis in patients after ileoanal pull-through procedure. Ann Surg 1998;227(5): Okon A, Dubinsky M, Vasiliauskas EA, Papadakis KA, Ippoliti A, Targan SR, et al. Elevated platelet count before ileal pouchanal anastomosis for ulcerative colitis is associated with the development of chronic pouchitis. Am Surg 2005;71(10): Fleshner P, Ippoliti A, Dubinsky M, Ognibene S, Vasiliauskas E, Chelly M, et al. A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2007;5(8): Hata K, Watanabe T, Shinozaki M, Nagawa H. Patients with extraintestinal manifestations have a higher risk of developing pouchitis in ulcerative colitis: multivariate analysis. Scand J Gastroenterol 2003;38(10): Lohmuller JL, Pemberton JH, Dozois RR, Ilstrup D, van Heerden J. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg 1990;211(5): Shepherd NA, Hulten L, Tytgat GN, Nicholls RJ, Nasmyth DG, Hill MJ, et al. Pouchitis. Int J Colorectal Dis 1989;4(4): Fleshner PR, Vasiliauskas EA, Kam LY, Fleshner NE, Gaiennie J, Abreu-Martin MT, et al. High level perinuclear antineutrophil cytoplasmic antibody (panca) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 2001;49(5):671 7.
10 1236 S. Mukewar et al. 36. Kuisma J, Jarvinen H, Kahri A, Farkkila M. Factors associated with disease activity of pouchitis after surgery for ulcerative colitis. Scand J Gastroenterol 2004;39(6): Hui T, Landers C, Vasiliauskas E, Abreu M, Dubinsky M, Papadakis KA, et al. Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation. Dis Colon Rectum 2005;48(6): Merrett MN, Mortensen N, Kettlewell M, Jewell DO. Smoking may prevent pouchitis in patients with restorative proctocolectomy for ulcerative colitis. Gut 1996;38(3): Melmed GY, Fleshner PR, Bardakcioglu O, Ippoliti A, Vasiliauskas EA, Papadakis KA, et al. Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum 2008;51(1): Tyler AD, Milgrom R, Xu W, Stempak JM, Steinhart AH, McLeod RS, et al. Antimicrobial antibodies are associated with a Crohn's disease-like phenotype after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2012;10(5): Mukewar S, Wu X, Lopez R, Kiran RP, Remzi FH, Shen B. Ethnicity and the risk of development of Crohn's disease of the ileal pouch. J Crohns Colitis 2013;7(5):e Delaney CP, Remzi FH, Gramlich T, Dadvand B, Fazio VW. Equivalent function, quality of life and pouch survival rates after ileal pouch-anal anastomosis for indeterminate and ulcerative colitis. Ann Surg 2002;236(1): Hueting WE, Buskens E, van der Tweel I, Gooszen HG, van Laarhoven CJ. Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9,317 patients. Dig Surg 2005;22(1 2): Prudhomme M, Dehni N, Dozois RR, Tiret E, Parc R. Causes and outcomes of pouch excision after restorative proctocolectomy. Br J Surg 2006;93(1): Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 2003;125(6): Nicholls RJ. Review article: ulcerative colitis surgical indications and treatment. Aliment Pharmacol Ther 2002;16(Suppl 4): Sagap I, Remzi FH, Hammel JP, Fazio VW. Factors associated with failure in managing pelvic sepsis after ileal pouch-anal anastomosis (IPAA) a multivariate analysis. Surgery 2006;140(4): Tulchinsky H, Hawley PR, Nicholls J. Long-term failure after restorative proctocolectomy for ulcerative colitis. Ann Surg 2003; 238(2):
Risk Factors for Diseases of Ileal Pouch Anal Anastomosis After Restorative Proctocolectomy for Ulcerative Colitis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:81 89 Risk Factors for Diseases of Ileal Pouch Anal Anastomosis After Restorative Proctocolectomy for Ulcerative Colitis BO SHEN,* VICTOR W. FAZIO, FEZA
More informationRestorative Proctocolectomy For Ulcerative Colitis IN
590540SJS0010.1177/1457496915590540Restorative proctocolectomyi. Helavirta, H. Huhtala, M. Hyöty, P. Collin, P. Aitola research-article2015 Original article Restorative Proctocolectomy For Ulcerative Colitis
More informationORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:62 68 ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT Impact of Orthotopic Liver Transplant for Primary Sclerosing Cholangitis on Chronic Antibiotic
More informationCan We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA
Can We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA Endpoints Overview Hospitalization Surgery Colorectal cancer
More informationPouchitis and Cuffitis A bloody mess. Sze-Lin Peng Colorectal Surgeon Counties Manukau District Health Board
Pouchitis and Cuffitis A bloody mess Sze-Lin Peng Colorectal Surgeon Counties Manukau District Health Board Ileal-pouch anal anastomosis https://www.pennmedicine.org/for-health-care-professionals/for-physicians/physician-education-and-resources/clinicalbriefings/2018/february/total-proctocolectomy-with-jpouch-reconstruction-for-ulcerative-colitis
More informationSURGICAL MANAGEMENT OF ULCERATIVE COLITIS
SURGICAL MANAGEMENT OF ULCERATIVE COLITIS Cary B. Aarons, MD Associate Professor of Surgery Division of Colon & Rectal Surgery University of Pennsylvania AGENDA Background Diagnosis/Work-up Medical Management
More informationIleal Pouch Anal Anastomosis: The Preferred Method of Reconstruction after Proctocolectomy in Children
Ileal Pouch Anal Anastomosis: The Preferred Method of Reconstruction after Proctocolectomy in Children Stephanie Jones, D.O. Surgical Fellow March 21, 2011 Ulcerative Colitis Spectrum of inflammatory bowel
More informationMaintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice
Aliment Pharmacol Ther 2005; 22: 721 728. doi: 10.1111/j.1365-2036.2005.02642.x Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice B. SHEN*, A. BRZEZINSKI*,
More informationINFLAMMATORY BOWEL DISEASE. Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic
INFLAMMATORY BOWEL DISEASE Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic WHAT IS INFLAMMATORY BOWEL DISEASE (IBD)? Chronic inflammation of the intestinal tract Two related
More informationIleoanal Pouch Solves the Problem
Ileoanal Pouch Solves the Problem Bruce D George Department of Surgery John Radcliffe Hospital, Falk Symposium 2-3 May 2008 Ileoanal Pouch Solves the Problem? Sometimes Not always Key Issues in Pouch Surgery
More informationComplications and Functional Results after Ileoanal Pouch Formation in Obese Patients
J Gastrointest Surg (2008) 12:668 674 DOI 10.1007/s11605-008-0465-3 Complications and Functional Results after Ileoanal Pouch Formation in Obese Patients R. P. Kiran & F. H. Remzi & V. W. Fazio & I. C.
More informationWorld Journal of Colorectal Surgery
World Journal of Colorectal Surgery Volume 5, Issue 1 2015 Article 1 Ileal U Pouch Reconstruction Proximal To Straight Sublevator Ileoanal Anastomosis Following Total Proctocolectomy For Low Rectal Cancer
More informationPatho Basic Chronic Inflammatory Bowel Diseases. Jürg Vosbeck Pathology
Patho Basic Chronic Inflammatory Bowel Diseases Jürg Vosbeck Pathology General Group of chronic relapsing diseases with chronic bloody or watery diarrhea Usually ulcerative colitis (UC) or Crohn s disease
More informationChallenges in IBD: The Post-Op IBD Patient: Preventing Pouchitis & Recurrence
Challenges in IBD: The Post-Op IBD Patient: Preventing Pouchitis & Recurrence Sharon Dudley-Brown, PHD, FNP-BC, FAAN Assistant Professor Johns Hopkins University Baltimore, MD sdudley2@jhmi.edu Disclosures
More informationKalle Landerholm, Maie Abdalla, Pär Myrelid and Roland Andersson. Journal Article. Postprint available at: Linköping University Electronic Press
Survival of ileal pouch anal anastomosis constructed after colectomy or secondary to a previous ileorectal anastomosis in ulcerative colitis patients: a population-based cohort study Kalle Landerholm,
More informationFunctional outcome and quality of life after restorative proctocolectomy and ileo-anal pouch anastomosis
Original article Peer reviewed article SWISS MED WKLY 2009;139(13 14):193 197 www.smw.ch 193 Functional outcome and quality of life after restorative proctocolectomy and ileo-anal pouch anastomosis Philippe
More informationHomayoon Akbari, MD, PhD
Recent Advances in IBD Surgery Homayoon M. Akbari, MD, PhD, FRCS(C), FACS Associate Professor of Surgery Virginia Commonwealth University Crohn s disease first described as a surgical condition, with the
More informationIndex. Surg Clin N Am 87 (2007) Note: Page numbers of article titles are in boldface type.
Surg Clin N Am 87 (2007) 787 796 Index Note: Page numbers of article titles are in boldface type. A Abscesses in anorectal Crohn s disease, 622 intra-abdominal, in Crohn s disease, 590 591 perirectal,
More informationSurgical Management of IBD. Val Jefford Grand Rounds October 14, 2003
Surgical Management of IBD Val Jefford Grand Rounds October 14, 2003 Introduction Important Features Clinical Presentation Evaluation Medical Treatment Surgical Treatment Cases Overview Introduction Two
More informationPoor Outcomes of Complicated Pouch-Related Fistulas after Ileal Pouch-Anal Anastomosis Surgery
Syddansk Universitet Poor Outcomes of Complicated Pouch-Related Fistulas after Ileal Pouch-Anal Anastomosis Surgery Kjaer, M D; Kjeldsen, Jens; Qvist, Niels Published in: Scandinavian Journal of Surgery
More informationSurgical Approach to Crohn s Colitis Segmental or Total Colectomy? Can We Avoid the Stoma?
17 th Panhellenic IBD Congress Thessaloniki May 2018 Surgical Approach to Crohn s Colitis Segmental or Total Colectomy? Can We Avoid the Stoma? Janindra Warusavitarne Consultant Colorectal Surgeon, St
More information11/13/11. Biologics for CD and CUC: The Impact on Surgical Outcomes. Principles of Successful Intestinal Surgery
Biologics for CD and CUC: The Impact on Surgical Outcomes Robert R. Cima, M.D., M.A. Associate Professor of Surgery Division of Colon and Rectal Surgery Overview Antibody based medications (biologics)
More informationSurgery for Ulcerative Colitis 11/14/10. Colectomy for Ulcerative Colitis: What your patient should know. Surgery for Ulcerative Colitis
Colectomy for Ulcerative Colitis: What your patient should know Madhulika G. Varma MD Associate Professor and Chief Section of Colorectal Surgery University of California, San Francisco Surgery for Ulcerative
More informationIs stapled ileal pouch anal anastomosis a safe option in ulcerative colitis patients with dysplasia or cancer?
DOI 10.1007/s00384-009-0744-9 ORIGINAL ARTICLE Is stapled ileal pouch anal anastomosis a safe option in ulcerative colitis patients with dysplasia or cancer? O. Zmora & D. Spector & I. Dotan & J. M. Klausner
More informationClinical Approach to Diseases of Ileal Pouch-Anal Anastomosis
American Journal of Gastroenterology ISSN 0002-9270 C 2005 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2005.00278.x Published by Blackwell Publishing CLINICAL REVIEW Clinical Approach to
More informationCase Report Successful Long-Term Use of Infliximab in Refractory Pouchitis in an Adolescent
Gastroenterology Research and Practice Volume 2010, Article ID 860394, 4 pages doi:10.1155/2010/860394 Case Report Successful Long-Term Use of Infliximab in Refractory Pouchitis in an Adolescent Jessica
More informationChronic Refractory Pouch Dysfunction
Chronic Refractory Pouch Dysfunction Anatomy of Pelvic Pouches Afferent limb (neo-ti) Tip of J J S W Inlet Efferent limb Bo Shen, MD The Ed and Joey Story Endowed Chair Professor of Medicine The Cleveland
More informationReview article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease
Aliment Pharmacol Ther 23; 18 (Suppl. 2): 1 5. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease P. MUNKHOLM Department of Medical Gastroenterology, Hvidovre
More informationavailable at
Journal of Crohn's and Colitis (2008) 2, 142 151 available at www.sciencedirect.com Development of pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis: A role for serological
More informationConvegno Annuale Fondazione Rosa Gallo. Risultati chirurgici a lungo termine nelle IBD John Nicholls
Convegno Annuale Fondazione Rosa Gallo Verona 23 24 novembre 2010 Risultati chirurgici a lungo termine nelle IBD John Nicholls MORTALITY IN IBD Roberts et al BMJ 2007 Record Linkage Study Oxford Region
More informationIndex. Note: Page numbers of article title are in boldface type.
Index Note: Page numbers of article title are in boldface type. A Abscess(es) in Crohn s disease, 168 169 IPAA and, 110 114 as unexpected finding in colorectal surgery, 46 Adhesion(s) trocars-related laparoscopy
More informationInflammatory Bowel Disease: Updates and Controversies CASE #1 CASE #1 8/6/2015. What is the most likely diagnosis?
Inflammatory Bowel Disease: Updates and Controversies Tehttp://192.185.93.102/~paulkeij/wpcontent/uploads/2013/07/collaboration.jpgxt August 7, 2015 Meagan M Costedio, MD; Colorectal Surgery; Cleveland
More informationINFLAMMATORY BOWEL DISEASE ORIGINAL CONTRIBUTIONS
ORIGINAL CONTRIBUTIONS nature publishing group 881 see related editorial on page 888 Consecutive Monitoring of Fecal and for the Early Diagnosis and Prediction of Pouchitis after Restorative Proctocolectomy
More informationPrimary sclerosing cholangitis (PSC) is a chronic, cholestatic
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:540 546 Progressive Primary Sclerosing Cholangitis Requiring Liver Transplantation Is Associated With Reduced Need for Colectomy in Patients With Ulcerative
More informationCitation for published version (APA): Bartels, S. A. L. (2013). Laparoscopic colorectal surgery: beyond the short-term effects
UvA-DARE (Digital Academic Repository) Laparoscopic colorectal surgery: beyond the short-term effects Bartels, S.A.L. Link to publication Citation for published version (APA): Bartels, S. A. L. (2013).
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Ulcerative colitis: the management of ulcerative colitis Quality standard title: Ulcerative
More informationGastrointestinal Imaging Original Research
Contrast Enema for Detecting nastomotic Strictures Gastrointestinal Imaging Original Research David Dolinsky 1 Marc S. Levine 1 Stephen E. Rubesin 1 Igor Laufer 1 John L. Rombeau 2 Dolinsky D, Levine MS,
More informationPEDIATRIC INFLAMMATORY BOWEL DISEASE
PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease
More informationTreatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG
Treatment of Inflammatory Bowel Disease Michael Weiss MD, FACG What is IBD? IBD is an immune-mediated chronic intestinal disorder, characterized by chronic or relapsing inflammation within the GI tract.
More informationSurgery in Inflammatory Bowel Disease. Rajesh Gupta MS, MCh Surgical Gastroenterology Division Dept of General Surgery PGIMER, Chandigarh
Surgery in Inflammatory Bowel Disease Rajesh Gupta MS, MCh Surgical Gastroenterology Division Dept of General Surgery PGIMER, Chandigarh 1 Ulcerative colitis (UC) Ulcerative colitis (UC) characterized
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More informationPredicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium
Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationColostomy & Ileostomy
Colostomy & Ileostomy Indications, problems and preference By Waleed Omar Professor of Colorectal surgery, Mansoura University. Disclosure I have no disclosures. Presentation outline Stoma: Definition
More informationResponse to First Intravenous Steroid Therapy Determines the Subsequent Risk of Colectomy in Ulcerative Colitis Patients
Response to First Intravenous Steroid Therapy Determines the Subsequent Risk of Colectomy in Ulcerative Colitis Patients Tamás Molnár 1, Klaudia Farkas 1, Tibor Nyári 2, Zoltán Szepes 1, Ferenc Nagy 1,
More informationInflammatory Bowel Disease
Inflammatory Bowel Disease William Sonnenberg, MD Titusville, PA Disclosure Dr. William Sonnenberg has no conflict of interest, financial agreement, or working affiliation with any group or organization.
More informationComparison of outcomes for patients with primary sclerosing cholangitis associated with ulcerative colitis and Crohn s disease
Gastroenterology Report, 4(1), 2016, 43 49 doi: 10.1093/gastro/gou074 Advance Access Publication Date: 29 October 2014 Original article ORIGINAL ARTICLE Comparison of outcomes for patients with primary
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationCLINICAL MANAGEMENT. Clinical Management of Pouchitis. Clinical Case. Background
GASTROENTEROLOGY 2004;127:1809 1814 CLINICAL MANAGEMENT Loren Laine, M.D. Clinical Management Editor University of Southern California Los Angeles, California Clinical Management of Pouchitis WILLIAM J.
More informationINFLAMMATORY BOWEL DISEASE
National University Faculty of Medicine INFLAMMATORY BOWEL DISEASE Gehan M. Osman, MD. MBBS Pediatrician Jaffar Ibn Auf Specialized Hospital EDUCATIONAL OBJECTIVES Definitions and spectrum of (IBD) Epidemiology
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More informationAngie Perrin Lead Nurse/Clinical Nurse Specialist Oxford Radcliffe Hospitals NHS Trust
Angie Perrin Lead Nurse/Clinical Nurse Specialist Oxford Radcliffe Hospitals NHS Trust Background Late in 20th century saw revolutionary surgical advances within colorectal sphere 1978 Parks & Nicholls
More informationImplementation of disease and safety predictors during disease management in UC
Implementation of disease and safety predictors during disease management in UC DR ARIELLA SHITRIT DIGESTIVE DISEASES INSTITUTE SHAARE ZEDEK MEDICAL CENTER JERUSALEM Case presentation A 52 year old male
More informationIleo-rectal anastomosis for Crohn's disease of
Ileo-rectal anastomosis for Crohn's disease of the colon W. N. W. BAKER From the Research Department, St Mark's Hospital, London Gut, 1971, 12, 427-431 SUMMARY Twenty-six cases of Crohn's disease of the
More informationPredicting a Change in Diagnosis From Ulcerative Colitis to Crohn s Disease: A Nested, Case-Control Study
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:602 608 Predicting a Change in Diagnosis From Ulcerative Colitis to Crohn s Disease: A Nested, Case-Control Study GIL Y. MELMED,* ROBERT ELASHOFF, GARY C.
More informationDifferentiation Between Ileocecal Tuberculosis and Crohn s Disease using a Combination of Clinical, Endoscopic and Histological Characteristics
38 Original Article Differentiation Between Ileocecal Tuberculosis and Crohn s Disease using a Combination of Clinical, Endoscopic and Histological Characteristics Anuchapreeda S Leelakusolvong S Charatcharoenwitthaya
More informationORIGINAL ARTICLE. Surgery for Ulcerative Colitis in Elderly Persons. Changes in Indications for Surgery and Outcome Over Time
ORIGINAL ARTICLE Surgery for Ulcerative Colitis in Elderly Persons Changes in Indications for Surgery and Outcome Over Time Gidon Almogy, MD; David B. Sachar, MD; Carol A. Bodian, DrPH; Adrian J. Greenstein,
More informationCrohn s Disease. Resident Lecture 1/17/19
Crohn s Disease Resident Lecture 1/17/19 Objectives Features/Classification of Crohn s Disease Medical Treatment Surgical Indications Surgical Considerations 2 Case 25 yo F presents to your office with
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationAnus,Rectum and Colon
JOURNAL OF THE Anus,Rectum and Colon dx.doi.org/10.23922/jarc.2016-008 http://journal-arc.jp ORIGINAL RESEARCH ARTICLE Association between serum tumor necrosis factor-alpha level and the efficacy of infliximab
More informationSurgery for Inflammatory Bowel Disease
Surgery for Inflammatory Bowel Disease Emily Steinhagen, MD Assistant Professor Department of Surgery, Division of Colorectal Surgery University Hospitals Cleveland Medical Center Common Questions Why
More informationManagement of refractory fistulizing pouchitis with infliximab
European Review for Medical and Pharmacological Sciences Management of refractory fistulizing pouchitis with infliximab A. VISCIDO, A. KOHN *, C. PAPI **, R. CAPRILLI GI Unit, Department of Clinical Sciences,
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationQuality of life in ulcerative colitis patients treated medically versus patients undergoing surgery
European Review for Medical and Pharmacological Sciences Quality of life in ulcerative colitis patients treated medically versus patients undergoing surgery R. PICA, C. CASSIERI 1, A.M. PRONIO 2, M. ZIPPI,
More informationSalvage surgery after restorative proctocolectomy
Review Salvage surgery after restorative proctocolectomy H.Tulchinsky,C.R.G.CohenandR.J.Nicholls St Mark s Hospital, North West London Hospitals NHS Trust, Watford Road, Harrow HA1 3UJ, UK Correspondence
More informationIBD Tools to Aid in the Accurate Diagnosis of Inflammatory Bowel Disease
IBD Tools to Aid in the Accurate Diagnosis of Inflammatory Bowel Disease Inflammatory Bowel Disease Experts in Autoimmunity Inova Diagnostics offers a complete array of methods to aid in the diagnosis
More informationULCERATIVE COLITIS. Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC
ULCERATIVE COLITIS Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC What is Ulcerative Colitis? Ulcerative colitis (UC) is a disease marked by inflammation
More informationThirty-Day Outcomes of Laparoscopic vs. Open Total Proctocolectomy with Ileoanal Anastomosis in Children
Thirty-Day Outcomes of Laparoscopic vs. Open Total Proctocolectomy with Ileoanal Anastomosis in Children Jeremy D. Kauffman MD, Paul D. Danielson MD, Nicole M. Chandler MD Johns Hopkins All Children s
More informationThe role of Surgery and Stomas in IBD
The role of Surgery and Stomas in IBD When do I need it? Can I avoid it? How do I live with it? Kyle G. Cologne, MD Assistant Professor of Surgery USC Division of Colorectal Surgery Topics Surgical Differences
More informationSurgical Therapies for the Treatment of IBD!
Surgical Therapies for the Treatment of IBD! Andrew A Shelton, MD Clinical Professor of Surgery Stanford Hospital and Clinics Section of Colon and Rectal Surgery! Ulcerative Colitis v. Crohn s! 30% of
More informationInflammatory Bowel Disease When is diarrhea not just diarrhea?
Inflammatory Bowel Disease When is diarrhea not just diarrhea? Jackie Kazik, MA, PA C CME Resources CAPA Annual Conference, 2011 Inflammatory Bowel Disease Objectives Discuss what is known about the pathophysiology
More informationReview. Risks and benefits of ileal pouch anal anastomosis for ulcerative colitis. Udayakumar Navaneethan 1, Preethi GK Venkatesh 1 & Bo Shen 1
Review Risks and benefits of ileal pouch anal anastomosis for ulcerative colitis Restorative proctocolectomy with ileal pouch anal anastomosis (IPAA) is the surgical treatment of choice for patients with
More informationIleal pouchyanal anastomosis (IPAA) is the procedure
ORIGINAL CONTRIBUTION Proximal Diversion at the Time of Ileal Pouch Anal Anastomosis for Ulcerative Colitis: Current Practices of North American Colorectal Surgeons Sandra L. de Montbrun, M.D. & Paul M.
More informationSurgical Management of IBD in the Age of Biologics
Surgical Management of IBD in the Age of Biologics Lisa S. Poritz, M.D Associate Professor of Surgery Division of Colon and Rectal Surgery Objectives Discuss surgical management of IBD When to operate
More informationPerianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
More informationThe Role of Surgery in Inflammatory Bowel Disease. Cory D Barrat, MD Colon and Rectal Surgeon Mercy Health
The Role of Surgery in Inflammatory Bowel Disease Cory D Barrat, MD Colon and Rectal Surgeon Mercy Health THANKS FOR INVITING ME! I have no financial disclosures Outline - Who am I and what do I do? -
More informationResearch Article Temporary Fecal Diversion in the Management of Colorectal and Perianal Crohn s Disease
Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2015, Article ID 286315, 5 pages http://dx.doi.org/10.1155/2015/286315 Research Article Temporary Fecal Diversion in the Management
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationDisease behavior in adult patients- are there predictors for stricture or fistula formation?
Disease behavior in adult patients- are there predictors for stricture or fistula formation? Falk Symposium 168, Madrid, Spain Iris Dotan, M.D., Head, IBD Center, Department of Gastroenterology and Liver
More informationSurgery and Stomas in IBD When do I need it? Can I avoid it? How do I live with it?
Surgery and Stomas in IBD When do I need it? Can I avoid it? How do I live with it? Kyle G. Cologne, MD Assistant Professor of Surgery USC Division of Colorectal Surgery Topics Surgical Differences between
More informationLong-term outcome after infliximab for refractory ulcerative colitis
Journal of Crohn's and Colitis (2008) 2, 219 225 available at www.sciencedirect.com Long-term outcome after infliximab for refractory ulcerative colitis Marc Ferrante a, Séverine Vermeire a, Herma Fidder
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationThe variable risk of colorectal cancer in patients with inflammatory bowel disease.
The variable risk of colorectal cancer in patients with inflammatory bowel disease. Lindgren, Stefan Published in: European Journal of Internal Medicine DOI: 10.1016/j.ejim.2004.12.001 Published: 2005-01-01
More informationThe first 1 0 years' experience of restorative proctocolectomy for ulcerative colitis
1070 St Mark's Hospital, City Road, London P Setti-Carraro J K Ritchie K H Wilkinson R J Nicholls P R Hawley Correspondence to: Mr R J Nicholls, St Mark's Hospital, City Road, London EC1V 2PS. Accepted
More informationSurgical Treatment of Inflammatory Bowel Disease (IBD)
Surgical Treatment of Inflammatory Bowel Disease (IBD) JMAJ 45(2): 55 62, 2002 Tetsuichiro MUTO Vice-Director, Cancer Institute Hospital Abstract: IBD, especially ulcerative colitis (UC) and Crohn s disease
More informationRestorative proctocolectomy with ileal pouch anal anastomosis. Clostridium difficile Infection in Patients With Ileal Pouch Anal Anastomosis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:782 788 Clostridium difficile Infection in Patients With Ileal Pouch Anal Anastomosis BO SHEN,* ZHI DONG JIANG, VICTOR W. FAZIO, FEZA H. REMZI, LILIANA RODRIGUEZ,
More informationPrevention, Diagnosis, and Treatment of Complications of the IPAA for Ulcerative Colitis
RESIDENT S CORNER Prevention, Diagnosis, and Treatment of Complications of the IPAA for Ulcerative Colitis Stefan D. Holubar, M.D., M.S. Department of Colon & Rectal Surgery, Digestive Disease and Surgery
More informationHistopathological evaluation and risk factors related to the development of pouchitis in patients with ileal pouches for ulcerative colitis
DOI:10.6061/clinics/2012(07)02 CLINICAL SCIENCE Histopathological evaluation and risk factors related to the development of pouchitis in patients with ileal pouches for ulcerative colitis Roberta Thiery
More informationThe Spectrum of IBD. Inflammatory Bowel Disease. Symptoms. Epidemiology. Tests for IBD. CD or UC? Inflamatory Bowel Disease. Fernando Vega, M.D.
The Spectrum of IBD Inflammatory Bowel Disease Fernando Vega, M.D. Epidemiology CD and UC together 1:400 UC Prevalence 1:500 UC Incidence 6-12K/annum CD Prevalence 1:1000 CD Incidence 3-6K/annum Symptoms
More informationSURGERY FOR COLITIS THE BOTTOM LINE
SURGERY FOR COLITIS THE BOTTOM LINE Speaker Declarations This presenter has the following declarations of relationship with industry None [Nov 2017] Surgeons just like to cut.. ABSOLUTE INDICATIONS Toxic
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationClinical Trials in IBD. Bruce Yacyshyn MD Professor of Medicine Division of Digestive Diseases
Clinical Trials in IBD Bruce Yacyshyn MD Professor of Medicine Division of Digestive Diseases Objectives Today s discussion will address the following topics: Similarities and differences between Crohn
More informationInflammatory Bowel Disease and Surgery: What You Should Know
Inflammatory Bowel Disease and Surgery: What You Should Know Ask the Experts March 9, 2019 Kristen Blaker, MD Colon and Rectal Surgery MetroHealth Medical Center Disclosures None Outline Who undergoes
More informationNON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente
NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND Fabrizio Parente Gastrointestinal Unit, A.Manzoni Hospital, Lecco & L.Sacco School of Medicine,University of Milan - Italy
More informationP rimary sclerosing cholangitis (PSC) is a chronic cholestatic
91 INFLAMMATORY BOWEL DISEASE PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis E V Loftus Jr, G C Harewood, C G Loftus, W J Tremaine, W S Harmsen, A R
More informationPercent Cumulative. Probability. Penetrating. Inflammatory. Stricturing. Months Patients at risk N =
Fistulizing Crohn s Disease Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology & Hepatology Mayo Clinic Rochester, Minnesota, USA Outline Fistulizing Crohn s Etiology Incidence
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationAAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease
AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty
More information